Idioma:

Selexipag for the Treatment of Pulmonary Arterial Hypertension

Sitbon, Olivier ; Channick, Richard ; Chin, Kelly M ; Frey, Aline ; Gaine, Sean ; Galiè, Nazzareno ; Ghofrani, Hossein-Ardeschir ; Hoeper, Marius M ; Lang, Irene M ; Preiss, Ralph ; Rubin, Lewis J ; Di Scala, Lilla ; Tapson, Victor ; Adzerikho, Igor ; Liu, Jinming ; Moiseeva, Olga ; Zeng, Xiaofeng ; Simonneau, Gérald ; McLaughlin, Vallerie V

The New England journal of medicine, 2015-12, Vol.373 (26), p.2522-2533 [Revista revisada por pares]

United States: Massachusetts Medical Society

Texto completo disponible

Citas Citado por

Acciones

Título:
Selexipag for the Treatment of Pulmonary Arterial Hypertension
Autor: Sitbon, Olivier ; Channick, Richard ; Chin, Kelly M ; Frey, Aline ; Gaine, Sean ; Galiè, Nazzareno ; Ghofrani, Hossein-Ardeschir ; Hoeper, Marius M ; Lang, Irene M ; Preiss, Ralph ; Rubin, Lewis J ; Di Scala, Lilla ; Tapson, Victor ; Adzerikho, Igor ; Liu, Jinming ; Moiseeva, Olga ; Zeng, Xiaofeng ; Simonneau, Gérald ; McLaughlin, Vallerie V
Materias: Acetamides - adverse effects ; Acetamides - therapeutic use ; Aged ; Circulatory system ; Clinical trials ; Committees ; Diarrhea ; Disease Progression ; Double-Blind Method ; Double-blind studies ; Drug Administration Schedule ; Drug dosages ; Drug therapy ; Endothelins ; Fees & charges ; Female ; Headache ; Hospitalization - statistics & numerical data ; Humans ; Hypertension ; Hypertension, Pulmonary - complications ; Hypertension, Pulmonary - drug therapy ; Hypertension, Pulmonary - mortality ; Jaw ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Nausea ; Pain ; Patients ; Pharmaceuticals ; Phosphodiesterase ; Prodrugs - adverse effects ; Prodrugs - therapeutic use ; Prostacyclin ; Pulmonary arteries ; Pulmonary hypertension ; Pyrazines - adverse effects ; Pyrazines - therapeutic use ; Statistical analysis ; Substance abuse treatment
Es parte de: The New England journal of medicine, 2015-12, Vol.373 (26), p.2522-2533
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-News-3
content type line 23
Descripción: Among over 1100 patients with pulmonary arterial hypertension who received selexipag, an oral selective IP prostacyclin-receptor agonist, or placebo, the risk of the composite end point of death or complication was lower with selexipag than with placebo at 1.3 years of follow-up. Pulmonary arterial hypertension is a severe disease with a poor prognosis despite available treatment options. 1 Current recommendations support the use of a combination of therapies that target the endothelin, nitric-oxide, and prostacyclin pathways. 2 , 3 Despite the benefits of intravenous prostacyclin therapy, 2 , 4 many patients with pulmonary arterial hypertension die without ever receiving this treatment. 5 , 6 The burden and risks related to the administration of prostacyclin therapy are probably contributing factors. 7 Selexipag is an oral selective IP prostacyclin-receptor agonist that is structurally distinct from prostacyclin. 8 – 11 In a placebo-controlled, phase 2 trial involving patients who were already receiving treatment for pulmonary . . .
Editor: United States: Massachusetts Medical Society
Idioma: Inglés

Enlaces

Volver a la lista de resultados

Anterior Resultado 9 Siguiente Ir a la siguiente página

Realización: Logos de Redes Sociales:

Selexipag for the Treatment of Pulmonary Arterial Hypertension

United States: Massachusetts Medical Society

Buscando en bases de datos remotas, por favor espere